Anonymous15 days ago
Eli Lilly's retatrutide, the first triple-hormone receptor agonist, has cleared its first late-stage diabetes trial with record-breaking weight loss of up to 16.8% at 40 weeks and HbA1c reductions of up to 2.0%, while earlier obesity data showed 28.7% weight loss at 68 weeks — far surpassing competitors. But a new neurological safety signal, questions about lifetime drug dependency, and a healthcare system already buckling under $71.7 billion in annual GLP-1 spending raise urgent questions about who will actually benefit from this next-generation treatment.